1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
VitaSpring Biomedical Co. Ltd.

VitaSpring Biomedical Co. Ltd.

VSBC
VitaSpring Biomedical Co. Ltd.US flagOther OTC
0.01
USD
- -
- -
2.30MMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
0.03
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
-0.02
-0.01
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
-0.02
-0.02
-0.03
-0.03
-0.03
Tangible Book Value per Share
- -
- -
- -
- -
- -
0.01
-0.01
-0.02
-0.02
-0.02
-0.02
Basic Weighted Avg Shares
55
55
55
55
91
206
207
207
207
207
207
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
6
- -
- -
- -
- -
- -
Operating Margin (%)
- -
-39.27
-128.74
-128.71
-171.12
20.07
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
1
-4
-1
-1
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
19.27
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-39.27
-130.36
45.7
-171.39
16.2
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
1
-3
-3
-4
-4
-5
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
2
-2
-3
-4
-4
-5
Return on Invested Capital (%)
- -
- -
- -
-340.93
- -
77.46
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Oct'26
Jan'26
Apr'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
207
207
207
Market Capitalization
207
207
2

Working Capital

FRC

•

in mil. unless spec.
Oct'26
Jan'26
Apr'27
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
5
Payables & Accruals
3
3
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
271.03%
10.34%
Free Cash Flow
- -
88.25%
-81.68%
Net Income, GAAP
- -
-204.39%
-46.4%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Ssu-Chuan Lai
Full Time Employees
1
Sector
Healthcare
Industry
Biotechnology
Address
400 Spectrum Center Drive Riverside CA United States of America 92618
IPO Date
Nov 13, 2019
CIK
0001697884
Website
vitaspringbio.com
Similar Companies
Apellis Pharmaceuticals, Inc. (APLS)
Trillium Therapeutics Inc. (TRIL.TO)
Xenetic Biosciences, Inc. (XBIOW)
Merus N.V. (MRUS)
Chemomab Therapeutics Ltd. (CMMB)
CGRM Genetiko JSC (GECO.ME)
Business
VitaSpring Biomedical Co. Ltd. (VSBC) develops and commercializes regenerative therapies focused on stem cell and exosome technologies sourced from placental tissue; the company offers VitaSpring Mesenchymal Stem Cells (X.msc), which are multipotent cells possessing maternal genes for tissue regeneration and repair, and Exosomes (X.exo) with elevated growth factors exhibiting anti-inflammatory and pro-epidermal repair properties for applications in immune diseases, preventive healthcare, cosmetics, and anti-aging treatments. Incorporated in 2016 and headquartered at 400 Spectrum Center Drive, Suite 1620, Irvine, California, VitaSpring operates a GTP laboratory employing proprietary homogeneous purification technology, high-specification flow cytometry, and strict quality controls to produce high-purity, viable clinical-grade cells; it targets global markets in biotechnology and pharmaceuticals through research-driven projects addressing unmet needs in regenerative medicine. The company, formerly known as Shemn Corp., changed its name in February 2020 to reflect its biomedical focus; it maintains limited revenue from product sales while pursuing equity financing, shareholder advances, strategic partnerships, and licensing opportunities to fund ongoing research, regulatory initiatives, and commercialization amid liquidity constraints noted in its fiscal year 2023 annual report.